318 results on '"Pickering, Lisa"'
Search Results
2. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)
- Author
-
Dayimu, Alimu, Gupta, Avinash, Matin, Rubeta N., Nobes, Jenny, Board, Ruth, Payne, Miranda, Rao, Ankit, Fusi, Alberto, Danson, Sarah, Eccles, Bryony, Carser, Judith, Brown, Ciara O’Hanlon, Steven, Neil, Bhattacharyya, Madhumita, Brown, Ewan, Gonzalez, Michael, Highley, Martin, Pickering, Lisa, Kumar, Satish, Waterston, Ashita, Burghel, George, Demain, Leigh, Baker, Eleanor, Wulff, Jerome, Qian, Wendi, Twelves, Sophie, Middleton, Mark, and Corrie, Pippa
- Published
- 2024
- Full Text
- View/download PDF
3. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
- Author
-
Wong, Selina K., Blum, Steven M., Sun, Xiaopeng, Da Silva, Inês P., Zubiri, Leyre, Ye, Fei, Bai, Kun, Zhang, Kevin, Ugurel, Selma, Zimmer, Lisa, Livingstone, Elisabeth, Schadendorf, Dirk, Serra-Bellver, Patricio, Muñoz-Couselo, Eva, Ortiz, Carolina, Lostes, Julia, Huertas, Roberto M., Arance, Ana, Pickering, Lisa, Long, Georgina V., Carlino, Matteo S., Buchbinder, Elizabeth I., Vázquez-Cortés, Leticia, Jara-Casas, Diego, Márquez-Rodas, Iván, González-Espinoza, Iván R., Balko, Justin M., Menzies, Alexander M., Sullivan, Ryan J., and Johnson, Douglas B.
- Published
- 2023
- Full Text
- View/download PDF
4. Metastatic Renal Cancer: Systemic Therapy
- Author
-
Liu, Wing Kin, Afshar, Mehran, Pickering, Lisa, Anderson, Christopher, editor, and Afshar, Mehran, editor
- Published
- 2022
- Full Text
- View/download PDF
5. REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers
- Author
-
Merrick, Sophie, Nankivell, Matthew, Quartagno, Matteo, Clarke, Caroline S., Joharatnam-Hogan, Nalinie, Waddell, Tom, O'Carrigan, Brent, Seckl, Michael, Ghorani, Ehsan, Banks, Emma, Edmonds, Kim, Bray, George, Woodward, Rose, Bennett, Rachel, Badrock, Jonathan, Hudson, Will, Langley, Ruth E., Vasudev, Naveen, Pickering, Lisa, and Gilbert, Duncan C.
- Published
- 2023
- Full Text
- View/download PDF
6. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
- Author
-
Serra-Bellver, Patricio, Versluis, Judith M., Oberoi, Honey K., Zhou, Cong, Slattery, Timothy D., Khan, Yasir, Patrinely, James R., Pires da Silva, Inês, Martínez-Vila, C., Cook, Natalie, Graham, Donna M., Carlino, Matteo S., Menzies, Alexander M., Arance, Ana M., Johnson, Douglas B., Long, Georgina V., Pickering, Lisa, Larkin, James M.G., Blank, Christian U., and Lorigan, Paul
- Published
- 2022
- Full Text
- View/download PDF
7. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: Including myocarditis and the new entity of non inflammatory left ventricular dysfunction
- Author
-
Andres, Maria Sol, Ramalingam, Sivatharshini, Rosen, Stuart D., Baksi, John, Khattar, Rajdeep, Kirichenko, Yulia, Young, Kate, Yousaf, Nadia, Okines, Alicia, Huddart, Robert, Harrington, Kevin, Furness, Andrew J.S., Turajlic, Samra, Pickering, Lisa, Popat, Sanjay, Larkin, James, and Lyon, Alexander R.
- Published
- 2022
- Full Text
- View/download PDF
8. VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis
- Author
-
Nicholson, Steve, Tovey, Holly, Elliott, Tony, Burnett, Stephanie M., Cruickshank, Clare, Bahl, Amit, Kirkbride, Peter, Mitra, Anita V., Thomson, Alastair H., Vasudev, Naveen, Venugopal, Balaji, Slade, Rachel, Tregellas, Lucy, Morgan, Bruno, Hassall, Alison, Hall, Emma, and Pickering, Lisa M.
- Published
- 2022
- Full Text
- View/download PDF
9. Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study
- Author
-
Fu, Xiao, Zhao, Yue, Lopez, Jose I., Rowan, Andrew, Au, Lewis, Fendler, Annika, Hazell, Steve, Xu, Hang, Horswell, Stuart, Shepherd, Scott T. C., Spencer, Charlotte E., Spain, Lavinia, Byrne, Fiona, Stamp, Gordon, O’Brien, Tim, Nicol, David, Augustine, Marcellus, Chandra, Ashish, Rudman, Sarah, Toncheva, Antonia, Furness, Andrew J. S., Pickering, Lisa, Kumar, Santosh, Koh, Dow-Mu, Messiou, Christina, Dafydd, Derfel ap, Orton, Matthew R., Doran, Simon J., Larkin, James, Swanton, Charles, Sahai, Erik, Litchfield, Kevin, Turajlic, Samra, and Bates, Paul A.
- Published
- 2022
- Full Text
- View/download PDF
10. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
- Author
-
Fendler, Annika, Shepherd, Scott T. C., Au, Lewis, Wilkinson, Katalin A., Wu, Mary, Byrne, Fiona, Cerrone, Maddalena, Schmitt, Andreas M., Joharatnam-Hogan, Nalinie, Shum, Benjamin, Tippu, Zayd, Rzeniewicz, Karolina, Boos, Laura Amanda, Harvey, Ruth, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Sarker, Sarah, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Korteweg, Justine, Foley, Tara, Bazin, Jessica, Gordon, William, Barber, Taja, Emslie-Henry, Andrea, Xie, Wenyi, Gerard, Camille L., Deng, Daqi, Wall, Emma C., Agua-Doce, Ana, Namjou, Sina, Caidan, Simon, Gavrielides, Mike, MacRae, James I., Kelly, Gavin, Peat, Kema, Kelly, Denise, Murra, Aida, Kelly, Kayleigh, O’Flaherty, Molly, Dowdie, Lauren, Ash, Natalie, Gronthoud, Firza, Shea, Robyn L., Gardner, Gail, Murray, Darren, Kinnaird, Fiona, Cui, Wanyuan, Pascual, Javier, Rodney, Simon, Mencel, Justin, Curtis, Olivia, Stephenson, Clemency, Robinson, Anna, Oza, Bhavna, Farag, Sheima, Leslie, Isla, Rogiers, Aljosja, Iyengar, Sunil, Ethell, Mark, Messiou, Christina, Cunningham, David, Chau, Ian, Starling, Naureen, Turner, Nicholas, Welsh, Liam, van As, Nicholas, Jones, Robin L., Droney, Joanne, Banerjee, Susana, Tatham, Kate C., O’Brien, Mary, Harrington, Kevin, Bhide, Shreerang, Okines, Alicia, Reid, Alison, Young, Kate, Furness, Andrew J. S., Pickering, Lisa, Swanton, Charles, Gandhi, Sonia, Gamblin, Steve, Bauer, David L. V., Kassiotis, George, Kumar, Sacheen, Yousaf, Nadia, Jhanji, Shaman, Nicholson, Emma, Howell, Michael, Walker, Susanna, Wilkinson, Robert J., Larkin, James, and Turajlic, Samra
- Published
- 2021
- Full Text
- View/download PDF
11. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
- Author
-
Fendler, Annika, Au, Lewis, Shepherd, Scott T. C., Byrne, Fiona, Cerrone, Maddalena, Boos, Laura Amanda, Rzeniewicz, Karolina, Gordon, William, Shum, Benjamin, Gerard, Camille L., Ward, Barry, Xie, Wenyi, Schmitt, Andreas M., Joharatnam-Hogan, Nalinie, Cornish, Georgina H., Pule, Martin, Mekkaoui, Leila, Ng, Kevin W., Carlyle, Eleanor, Edmonds, Kim, Rosario, Lyra Del, Sarker, Sarah, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Stone, Richard, Gomes, Camila, Flynn, Helen R., Agua-Doce, Ana, Hobson, Philip, Caidan, Simon, Howell, Michael, Wu, Mary, Goldstone, Robert, Crawford, Margaret, Cubitt, Laura, Patel, Harshil, Gavrielides, Mike, Nye, Emma, Snijders, Ambrosius P., MacRae, James I., Nicod, Jerome, Gronthoud, Firza, Shea, Robyn L., Messiou, Christina, Cunningham, David, Chau, Ian, Starling, Naureen, Turner, Nicholas, Welsh, Liam, van As, Nicholas, Jones, Robin L., Droney, Joanne, Banerjee, Susana, Tatham, Kate C., Jhanji, Shaman, O’Brien, Mary, Curtis, Olivia, Harrington, Kevin, Bhide, Shreerang, Bazin, Jessica, Robinson, Anna, Stephenson, Clemency, Slattery, Tim, Khan, Yasir, Tippu, Zayd, Leslie, Isla, Gennatas, Spyridon, Okines, Alicia, Reid, Alison, Young, Kate, Furness, Andrew J. S., Pickering, Lisa, Gandhi, Sonia, Gamblin, Steve, Swanton, Charles, Nicholson, Emma, Kumar, Sacheen, Yousaf, Nadia, Wilkinson, Katalin A., Swerdlow, Anthony, Harvey, Ruth, Kassiotis, George, Larkin, James, Wilkinson, Robert J., and Turajlic, Samra
- Published
- 2021
- Full Text
- View/download PDF
12. Red cell differential width (RDW) as a predictor of survival outcomes with palliative and adjuvant chemotherapy for metastatic penile cancer
- Author
-
Patel, Reena, English, Louise, Liu, Wing K., Tree, Alison C., Ayres, Benjamin, Watkin, Nick, Pickering, Lisa M., and Afshar, Mehran
- Published
- 2020
- Full Text
- View/download PDF
13. Perspectives on Neoadjuvant Clinical Trial Participation for Patients with Kidney Cancer: A Survey-Based Examination
- Author
-
Ntowe, Koumani W., McAdoo, Sallie, Haas, Naomi B., Karam, Jose A., Lara, Primo N., Fashoyin-Aje, Ibilola, Saraiya, Biren P., Maskens, Deborah, Pickering, Lisa, Master, Viraj A., Zhang, Tian, and Kaye, Deborah R.
- Abstract
Background: Kidney cancer is amongst the deadliest genitourinary malignancies. Neoadjuvant systemic therapy has the potential to improve survival and overall outcomes in select patients. Enrolling patients in trials of neoadjuvant treatment for kidney cancer is challenging, which limits neoadjuvant treatment development.Objective: This study aims to develop a better understanding of the barriers patients face in kidney cancer clinical trial participation, with a particular focus on neoadjuvant trials for renal cell carcinoma.Methods: From 2022–2023, we recruited participants with a history of kidney cancer through a Qualtrics survey that was sent to the Kidney Cancer Association (KCA) and Kidney Cancer Cure (KCCure) mailing lists and social media pages. Patient responses on demographics, clinical information, and perspectives were evaluated.Results: Ninety-four individuals completed the survey. Eighty-one percent of respondents reported not participating in clinical trials due to not being informed about potential applicable trials. Importantly, many (76%) respondents reported that prevention of cancer return was a highly important reason to participate in clinical trials. Most respondents reported a willingness to undergo a kidney biopsy (59%), and/or additional appointments (58%) and surgery delays.Conclusions: Increased patient awareness about clinical trials with the potential to delay cancer recurrence may increase patient participation in clinical trials. Clinical trial design, including additional appointments or interventions and/or minor surgery delays are not major barriers to trial participation.
- Published
- 2024
- Full Text
- View/download PDF
14. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
- Author
-
Vasudev, Naveen S., primary, Ainsworth, Gemma, additional, Brown, Sarah, additional, Pickering, Lisa, additional, Waddell, Tom, additional, Fife, Kate, additional, Griffiths, Richard, additional, Sharma, Anand, additional, Katona, Eszter, additional, Howard, Helen, additional, Velikova, Galina, additional, Maraveyas, Anthony, additional, Brown, Janet, additional, Pezaro, Carmel, additional, Tuthill, Mark, additional, Boleti, Ekaterini, additional, Bahl, Amit, additional, Szabados, Bernadett, additional, Banks, Rosamonde E., additional, Brown, Joanne, additional, Venugopal, Balaji, additional, Patel, Poulam, additional, Jain, Ankit, additional, Symeonides, Stefan N., additional, Nathan, Paul, additional, Collinson, Fiona J., additional, and Powles, Thomas, additional
- Published
- 2023
- Full Text
- View/download PDF
15. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)
- Author
-
Dayimu, Alimu, primary, Gupta, Avinash, additional, Matin, Rubeta N, additional, Nobes, Jenny, additional, Board, Ruth, additional, Payne, Miranda, additional, Rao, Ankit, additional, Fusi, Alberto, additional, Danson, Sarah, additional, Eccles, Bryony, additional, Carser, Judith, additional, Brown, Ciara O’Hanlon, additional, Steven, Neil, additional, Bhattacharyya, Madhumita, additional, Brown, Ewan, additional, Gonzalez, Michael, additional, Highley, Martin, additional, Pickering, Lisa, additional, Kumar, Satish, additional, Waterston, Ashita, additional, Burghel, George, additional, Demain, Leigh, additional, Baker, Eleanor, additional, Wulff, Jerome, additional, Qian, Wendi, additional, Twelves, Sophie, additional, Middleton, Mark, additional, and Corrie, Pippa, additional
- Published
- 2023
- Full Text
- View/download PDF
16. Malignant Melanoma
- Author
-
Larkin, James, primary and Pickering, Lisa, additional
- Published
- 2020
- Full Text
- View/download PDF
17. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study
- Author
-
Colomba, Emeline, Le Teuff, Gwénaël, Eisen, Tim, Stewart, Grant D., Fife, Kate, Larkin, James, Biondo, Andrea, Pickering, Lisa, Srinivasan, Anandagopal, Boyle, Helen, Derosa, Lisa, Sternberg, Cora N., Recine, Federica, Ralph, Christy, Saldana, Carolina, Barthélémy, Philippe, Bernhard, Jean Christophe, Gurney, Howard, Verhoest, Gregory, Vauleon, Elodie, Bigot, Pierre, Berger, Julien, Pfister, Christian, Gravis, Gwenaelle, Rodier, Jean-Michel, Culine, Stéphane, Caty, Armelle, Rolland, Frederic, Priou, Franck, Escudier, Bernard, and Albiges, Laurence
- Published
- 2017
- Full Text
- View/download PDF
18. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
- Author
-
Vasudev, Naveen S., Ainsworth, Gemma, Brown, Sarah, Pickering, Lisa, Waddell, Tom, Fife, Kate, Griffiths, Richard, Sharma, Anand, Katona, Eszter, Howard, Helen, Velikova, Galina, Maraveyas, Anthony, Brown, Janet, Pezaro, Carmel, Tuthill, Mark, Boleti, Ekaterini, Bahl, Amit, Szabados, Bernadett, Banks, Rosamonde E., and Brown, Joanne
- Published
- 2024
- Full Text
- View/download PDF
19. Data from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
- Author
-
Spain, Lavinia, primary, Coulton, Alexander, primary, Lobon, Irene, primary, Rowan, Andrew, primary, Schnidrig, Desiree, primary, Shepherd, Scott T.C., primary, Shum, Benjamin, primary, Byrne, Fiona, primary, Goicoechea, Maria, primary, Piperni, Elisa, primary, Au, Lewis, primary, Edmonds, Kim, primary, Carlyle, Eleanor, primary, Hunter, Nikki, primary, Renn, Alexandra, primary, Messiou, Christina, primary, Hughes, Peta, primary, Nobbs, Jaime, primary, Foijer, Floris, primary, van den Bos, Hilda, primary, Wardenaar, Rene, primary, Spierings, Diana C.J., primary, Spencer, Charlotte, primary, Schmitt, Andreas M., primary, Tippu, Zayd, primary, Lingard, Karla, primary, Grostate, Lauren, primary, Peat, Kema, primary, Kelly, Kayleigh, primary, Sarker, Sarah, primary, Vaughan, Sarah, primary, Mangwende, Mary, primary, Terry, Lauren, primary, Kelly, Denise, primary, Biano, Jennifer, primary, Murra, Aida, primary, Korteweg, Justine, primary, Lewis, Charlotte, primary, O'Flaherty, Molly, primary, Cattin, Anne-Laure, primary, Emmerich, Max, primary, Gerard, Camille L., primary, Pallikonda, Husayn Ahmed, primary, Lynch, Joanna, primary, Mason, Robert, primary, Rogiers, Aljosja, primary, Xu, Hang, primary, Huebner, Ariana, primary, McGranahan, Nicholas, primary, Al Bakir, Maise, primary, Murai, Jun, primary, Naceur-Lombardelli, Cristina, primary, Borg, Elaine, primary, Mitchison, Miriam, primary, Moore, David A., primary, Falzon, Mary, primary, Proctor, Ian, primary, Stamp, Gordon W.H., primary, Nye, Emma L., primary, Young, Kate, primary, Furness, Andrew J.S., primary, Pickering, Lisa, primary, Stewart, Ruby, primary, Mahadeva, Ula, primary, Green, Anna, primary, Larkin, James, primary, Litchfield, Kevin, primary, Swanton, Charles, primary, Jamal-Hanjani, Mariam, primary, and Turajlic, Samra, primary
- Published
- 2023
- Full Text
- View/download PDF
20. Supplementary Tables S1-S8 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
- Author
-
Spain, Lavinia, primary, Coulton, Alexander, primary, Lobon, Irene, primary, Rowan, Andrew, primary, Schnidrig, Desiree, primary, Shepherd, Scott T.C., primary, Shum, Benjamin, primary, Byrne, Fiona, primary, Goicoechea, Maria, primary, Piperni, Elisa, primary, Au, Lewis, primary, Edmonds, Kim, primary, Carlyle, Eleanor, primary, Hunter, Nikki, primary, Renn, Alexandra, primary, Messiou, Christina, primary, Hughes, Peta, primary, Nobbs, Jaime, primary, Foijer, Floris, primary, van den Bos, Hilda, primary, Wardenaar, Rene, primary, Spierings, Diana C.J., primary, Spencer, Charlotte, primary, Schmitt, Andreas M., primary, Tippu, Zayd, primary, Lingard, Karla, primary, Grostate, Lauren, primary, Peat, Kema, primary, Kelly, Kayleigh, primary, Sarker, Sarah, primary, Vaughan, Sarah, primary, Mangwende, Mary, primary, Terry, Lauren, primary, Kelly, Denise, primary, Biano, Jennifer, primary, Murra, Aida, primary, Korteweg, Justine, primary, Lewis, Charlotte, primary, O'Flaherty, Molly, primary, Cattin, Anne-Laure, primary, Emmerich, Max, primary, Gerard, Camille L., primary, Pallikonda, Husayn Ahmed, primary, Lynch, Joanna, primary, Mason, Robert, primary, Rogiers, Aljosja, primary, Xu, Hang, primary, Huebner, Ariana, primary, McGranahan, Nicholas, primary, Al Bakir, Maise, primary, Murai, Jun, primary, Naceur-Lombardelli, Cristina, primary, Borg, Elaine, primary, Mitchison, Miriam, primary, Moore, David A., primary, Falzon, Mary, primary, Proctor, Ian, primary, Stamp, Gordon W.H., primary, Nye, Emma L., primary, Young, Kate, primary, Furness, Andrew J.S., primary, Pickering, Lisa, primary, Stewart, Ruby, primary, Mahadeva, Ula, primary, Green, Anna, primary, Larkin, James, primary, Litchfield, Kevin, primary, Swanton, Charles, primary, Jamal-Hanjani, Mariam, primary, and Turajlic, Samra, primary
- Published
- 2023
- Full Text
- View/download PDF
21. Supplementary Figures S1-S25 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
- Author
-
Spain, Lavinia, primary, Coulton, Alexander, primary, Lobon, Irene, primary, Rowan, Andrew, primary, Schnidrig, Desiree, primary, Shepherd, Scott T.C., primary, Shum, Benjamin, primary, Byrne, Fiona, primary, Goicoechea, Maria, primary, Piperni, Elisa, primary, Au, Lewis, primary, Edmonds, Kim, primary, Carlyle, Eleanor, primary, Hunter, Nikki, primary, Renn, Alexandra, primary, Messiou, Christina, primary, Hughes, Peta, primary, Nobbs, Jaime, primary, Foijer, Floris, primary, van den Bos, Hilda, primary, Wardenaar, Rene, primary, Spierings, Diana C.J., primary, Spencer, Charlotte, primary, Schmitt, Andreas M., primary, Tippu, Zayd, primary, Lingard, Karla, primary, Grostate, Lauren, primary, Peat, Kema, primary, Kelly, Kayleigh, primary, Sarker, Sarah, primary, Vaughan, Sarah, primary, Mangwende, Mary, primary, Terry, Lauren, primary, Kelly, Denise, primary, Biano, Jennifer, primary, Murra, Aida, primary, Korteweg, Justine, primary, Lewis, Charlotte, primary, O'Flaherty, Molly, primary, Cattin, Anne-Laure, primary, Emmerich, Max, primary, Gerard, Camille L., primary, Pallikonda, Husayn Ahmed, primary, Lynch, Joanna, primary, Mason, Robert, primary, Rogiers, Aljosja, primary, Xu, Hang, primary, Huebner, Ariana, primary, McGranahan, Nicholas, primary, Al Bakir, Maise, primary, Murai, Jun, primary, Naceur-Lombardelli, Cristina, primary, Borg, Elaine, primary, Mitchison, Miriam, primary, Moore, David A., primary, Falzon, Mary, primary, Proctor, Ian, primary, Stamp, Gordon W.H., primary, Nye, Emma L., primary, Young, Kate, primary, Furness, Andrew J.S., primary, Pickering, Lisa, primary, Stewart, Ruby, primary, Mahadeva, Ula, primary, Green, Anna, primary, Larkin, James, primary, Litchfield, Kevin, primary, Swanton, Charles, primary, Jamal-Hanjani, Mariam, primary, and Turajlic, Samra, primary
- Published
- 2023
- Full Text
- View/download PDF
22. Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
- Author
-
Wu, Mary Y., primary, Shepherd, Scott T.C., additional, Fendler, Annika, additional, Carr, Edward J., additional, Au, Lewis, additional, Harvey, Ruth, additional, Dowgier, Giulia, additional, Hobbs, Agnieszka, additional, Herman, Lou S., additional, Ragno, Martina, additional, Adams, Lorin, additional, Schmitt, Andreas M., additional, Tippu, Zayd, additional, Shum, Benjamin, additional, Farag, Sheima, additional, Rogiers, Aljosja, additional, O’Reilly, Nicola, additional, Bawumia, Philip, additional, Smith, Callie, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Del Rosario, Lyra, additional, Lingard, Karla, additional, Mangwende, Mary, additional, Holt, Lucy, additional, Ahmod, Hamid, additional, Korteweg, Justine, additional, Foley, Tara, additional, Barber, Taja, additional, Hepworth, Stephanie, additional, Emslie-Henry, Andrea, additional, Caulfield-Lynch, Niamh, additional, Byrne, Fiona, additional, Deng, Daqi, additional, Williams, Bryan, additional, Brown, Michael, additional, Caidan, Simon, additional, Gavrielides, Mike, additional, MacRae, James I., additional, Kelly, Gavin, additional, Peat, Kema, additional, Kelly, Denise, additional, Murra, Aida, additional, Kelly, Kayleigh, additional, O’Flaherty, Molly, additional, Popat, Sanjay, additional, Yousaf, Nadia, additional, Jhanji, Shaman, additional, Tatham, Kate, additional, Cunningham, David, additional, Van As, Nicholas, additional, Young, Kate, additional, Furness, Andrew J.S., additional, Pickering, Lisa, additional, Beale, Rupert, additional, Swanton, Charles, additional, Gandhi, Sonia, additional, Gamblin, Steve, additional, Bauer, David L.V., additional, Kassiotis, George, additional, Howell, Michael, additional, Walker, Susanna, additional, Nicholson, Emma, additional, Larkin, James, additional, Wall, Emma C., additional, and Turajlic, Samra, additional
- Published
- 2023
- Full Text
- View/download PDF
23. Supplementary Tables and Figures from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
- Author
-
Armstrong, Andrew J., primary, Nixon, Andrew B., primary, Carmack, Andrea, primary, Yang, Qian, primary, Eisen, Tim, primary, Stadler, Walter M., primary, Jones, Robert J., primary, Garcia, Jorge A., primary, Vaishampayan, Ulka N., primary, Picus, Joel, primary, Hawkins, Robert E., primary, Hainsworth, John D., primary, Kollmannsberger, Christian K., primary, Logan, Theodore F., primary, Puzanov, Igor, primary, Pickering, Lisa M., primary, Ryan, Christopher W., primary, Protheroe, Andrew, primary, George, Daniel J., primary, and Halabi, Susan, primary
- Published
- 2023
- Full Text
- View/download PDF
24. Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
- Author
-
Armstrong, Andrew J., primary, Nixon, Andrew B., primary, Carmack, Andrea, primary, Yang, Qian, primary, Eisen, Tim, primary, Stadler, Walter M., primary, Jones, Robert J., primary, Garcia, Jorge A., primary, Vaishampayan, Ulka N., primary, Picus, Joel, primary, Hawkins, Robert E., primary, Hainsworth, John D., primary, Kollmannsberger, Christian K., primary, Logan, Theodore F., primary, Puzanov, Igor, primary, Pickering, Lisa M., primary, Ryan, Christopher W., primary, Protheroe, Andrew, primary, George, Daniel J., primary, and Halabi, Susan, primary
- Published
- 2023
- Full Text
- View/download PDF
25. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
- Author
-
Armstrong, Andrew J, Halabi, Susan, Eisen, Tim, Broderick, Samuel, Stadler, Walter M, Jones, Robert J, Garcia, Jorge A, Vaishampayan, Ulka N, Picus, Joel, Hawkins, Robert E, Hainsworth, John D, Kollmannsberger, Christian K, Logan, Theodore F, Puzanov, Igor, Pickering, Lisa M, Ryan, Christopher W, Protheroe, Andrew, Lusk, Christine M, Oberg, Sadie, and George, Daniel J
- Published
- 2016
- Full Text
- View/download PDF
26. Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
- Author
-
Spain, Lavinia, Coulton, Alexander, Lobon, Irene, Rowan, Andrew, Schnidrig, Desiree, Shepherd, Scott TC, Shum, Benjamin, Byrne, Fiona, Goicoechea, Maria, Piperni, Elisa, Au, Lewis, Edmonds, Kim, Carlyle, Eleanor, Hunter, Nikki, Renn, Alexandra, Messiou, Christina, Hughes, Peta, Nobbs, Jaime, Foijer, Floris, van den Bos, Hilda, Wardenaar, Rene, Spierings, Diana CJ, Spencer, Charlotte, Schmitt, Andreas M, Tippu, Zayd, Lingard, Karla, Grostate, Lauren, Peat, Kema, Kelly, Kayleigh, Sarker, Sarah, Vaughan, Sarah, Mangwende, Mary, Terry, Lauren, Kelly, Denise, Biano, Jennifer, Murra, Aida, Korteweg, Justine, Lewis, Charlotte, OFlaherty, Molly, Cattin, Anne-Laure, Emmerich, Max, Gerard, Camille L, Pallikonda, Husayn Ahmed, Lynch, Joanna, Mason, Robert, Rogiers, Aljosja, Xu, Hang, Huebner, Ariana, McGranahan, Nicholas, Al Bakir, Maise, Murai, Jun, Naceur-Lombardelli, Cristina, Borg, Elaine, Mitchison, Miriam, Moore, David A, Falzon, Mary, Proctor, Ian, Stamp, Gordon WH, Nye, Emma L, Young, Kate, Furness, Andrew JS, Pickering, Lisa, Stewart, Ruby, Mahadeva, Ula, Green, Anna, Larkin, James, Litchfield, Kevin, Swanton, Charles, Jamal-Hanjani, Mariam, Consortium, The PEACE, and Turajlic, Samra
- Subjects
Chemical Biology & High Throughput ,Signalling & Oncogenes ,Human Biology & Physiology ,Ecology,Evolution & Ethology ,Genome Integrity & Repair ,Tumour Biology ,Genetics & Genomics ,Computational & Systems Biology - Abstract
Understanding the evolutionary pathways to metastasis and resistance to immune checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here we present the most comprehensive intra-patient metastatic melanoma dataset assembled to date as part of the PEACE research autopsy programme, including 222 exome, 493 panel-sequenced, 161 RNA-seq, and 22 single-cell whole-genome sequencing samples from 14 ICI-treated patients. We observed frequent whole-genome doubling and widespread loss of heterozygosity, often involving antigen presentation machinery. We found KIT extrachromosomal DNA may have contributed to the lack of response to KIT inhibitors of a KIT-driven melanoma. At the lesion-level, MYC amplifications were enriched in ICI non-responders. Single-cell sequencing revealed polyclonal seeding of metastases originating from clones with different ploidy in one of the patients. Finally, we observed that brain metastases that diverged early in molecular evolution emerge late in disease. Overall, our study illustrates the diverse evolutionary landscape of advanced melanoma.
- Published
- 2023
- Full Text
- View/download PDF
27. Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study
- Author
-
Fu, Xiao, Zhao, Yue, Lopez, Jose I., Rowan, Andrew, Au, Lewis, Fendler, Annika, Hazell, Steve, Xu, Hang, Horswell, Stuart, Shepherd, Scott T. C., Spencer, Charlotte E., Spain, Lavinia, Byrne, Fiona, Stamp, Gordon, O’Brien, Tim, Nicol, David, Augustine, Marcellus, Chandra, Ashish, Rudman, Sarah, Toncheva, Antonia, Furness, Andrew J. S., Pickering, Lisa, Kumar, Santosh, Koh, Dow-Mu, Messiou, Christina, Dafydd, Derfel ap, Orton, Matthew R., Doran, Simon J., Larkin, James, Swanton, Charles, Sahai, Erik, Litchfield, Kevin, Turajlic, Samra, Ben Challacombe, Chowdhury, Simon, Drake, William, Fernando, Archana, Fotiadis, Nicos, Hatipoglu, Emine, Harrison-Phipps, Karen, Hill, Peter, Horsfield, Catherine, Marafioti, Teresa, Olsburgh, Jonathon, Polson, Alexander, Quezada, Sergio, Varia, Mary, Verma, Hema, and Bates, Paul A.
- Subjects
0303 health sciences ,Ecology ,Models, Biological ,Article ,Computational biology and bioinformatics ,Clonal Evolution ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Neoplasms ,Cancer genomics ,Molecular evolution ,Humans ,Ecology, Evolution, Behavior and Systematics ,030304 developmental biology - Abstract
Genetic intra-tumour heterogeneity fuels clonal evolution, but our understanding of clinically relevant clonal dynamics remain limited. We investigated spatial and temporal features of clonal diversification in clear cell renal cell carcinoma through a combination of modelling and real tumour analysis. We observe that the mode of tumour growth, surface or volume, impacts the extent of subclonal diversification, enabling interpretation of clonal diversity in patient tumours. Specific patterns of proliferation and necrosis explain clonal expansion and emergence of parallel evolution and microdiversity in tumours. In silico time-course studies reveal the appearance of budding structures before detectable subclonal diversification. Intriguingly, we observe radiological evidence of budding structures in early-stage clear cell renal cell carcinoma, indicating that future clonal evolution may be predictable from imaging. Our findings offer a window into the temporal and spatial features of clinically relevant clonal evolution., A combined modelling and tumour analysis approach is used to study the temporal and spatial patterns of subclone evolution in the TRACERx renal study. Studying the tumour shape and spatial features of clonal diversity in early-stage tumours may allow the prediction of tumour progression and patterns of subclone diversification over time.
- Published
- 2021
28. Management of Toxicity and Side Effects of Systemic Therapy for Renal Cell Carcinoma
- Author
-
Young, Kate, primary, Schmitt, Andreas M., additional, Mukherji, Deborah, additional, Spain, Lavinia, additional, Schmidinger, Manuela, additional, and Pickering, Lisa M., additional
- Published
- 2022
- Full Text
- View/download PDF
29. Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
- Author
-
Fendler, Annika, primary, Shepherd, Scott T.C., additional, Au, Lewis, additional, Wu, Mary, additional, Harvey, Ruth, additional, Wilkinson, Katalin A., additional, Schmitt, Andreas M., additional, Tippu, Zayd, additional, Shum, Benjamin, additional, Farag, Sheima, additional, Rogiers, Aljosja, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Del Rosario, Lyra, additional, Lingard, Karla, additional, Mangwende, Mary, additional, Holt, Lucy, additional, Ahmod, Hamid, additional, Korteweg, Justine, additional, Foley, Tara, additional, Barber, Taja, additional, Emslie-Henry, Andrea, additional, Caulfield-Lynch, Niamh, additional, Byrne, Fiona, additional, Deng, Daqi, additional, Kjaer, Svend, additional, Song, Ok-Ryul, additional, Queval, Christophe J., additional, Kavanagh, Caitlin, additional, Wall, Emma C., additional, Carr, Edward J., additional, Caidan, Simon, additional, Gavrielides, Mike, additional, MacRae, James I., additional, Kelly, Gavin, additional, Peat, Kema, additional, Kelly, Denise, additional, Murra, Aida, additional, Kelly, Kayleigh, additional, O’Flaherty, Molly, additional, Shea, Robyn L., additional, Gardner, Gail, additional, Murray, Darren, additional, Popat, Sanjay, additional, Yousaf, Nadia, additional, Jhanji, Shaman, additional, Tatham, Kate, additional, Cunningham, David, additional, Van As, Nicholas, additional, Young, Kate, additional, Furness, Andrew J.S., additional, Pickering, Lisa, additional, Beale, Rupert, additional, Swanton, Charles, additional, Gandhi, Sonia, additional, Gamblin, Steve, additional, Bauer, David L.V., additional, Kassiotis, George, additional, Howell, Michael, additional, Nicholson, Emma, additional, Walker, Susanna, additional, Wilkinson, Robert J., additional, Larkin, James, additional, and Turajlic, Samra, additional
- Published
- 2022
- Full Text
- View/download PDF
30. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis
- Author
-
Alexander, James L, primary, Ibraheim, Hajir, additional, Richards, Camellia, additional, Shum, Ben, additional, Pavlidis, Polychronis, additional, Hunter, Nikki, additional, Teare, Julian P, additional, Wotherspoon, Andrew, additional, Furness, Andrew, additional, Turajlic, Samra, additional, Pickering, Lisa, additional, Larkin, James, additional, Speight, Ally, additional, Papa, Sophie, additional, and Powell, Nick, additional
- Published
- 2022
- Full Text
- View/download PDF
31. Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers
- Author
-
Gulati, Sakshi, Martinez, Pierre, Joshi, Tejal, Birkbak, Nicolai Juul, Santos, Claudio R., Rowan, Andrew J., Pickering, Lisa, Gore, Martin, Larkin, James, Szallasi, Zoltan, Bates, Paul A., Swanton, Charles, and Gerlinger, Marco
- Published
- 2014
- Full Text
- View/download PDF
32. Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre.
- Author
-
Liu, Wing K, Patel, Reena, Crawford, Ruairidh, Ayres, Benjamin, Watkin, Nick, Tree, Alison, Pickering, Lisa, Patel, Hiten RH, and Ashfar, Mehran
- Abstract
Objective: This study aimed to provide real-world data on the multidisciplinary management of metastatic penile squamous-cell carcinoma (mpSCC) patients and their survival outcomes, particularly those who receive best supportive care (BSC). Methods: A retrospective analysis of 1720 patients, managed via a supra-regional penile-specialist multidisciplinary team was conducted between January 2006 and May 2020. Results: A total of 101 patients (median age 63 years; interquartile range 56–72 years; 73% ECOG 0/1) were included. Of these, 32% (32/101) had previously received adjuvant chemotherapy prior to metastatic recurrence, 58% (59/101) received chemotherapy and 42% (42/101) received BSC. Further, 17% (17/101) received second-line systemic therapy, and 3% (3/101) received third-line systemic therapy. For first-line systemic-therapy, there was a 46% (27/59) clinical benefit rate (CBR), with 9% (5/59) complete response, 15% (9/59) partial response and 22% (13/59) stable disease. Patients receiving second-line therapy (n =17) had a 29% (5/17) CBR. Median progression-free survival for first- and second-line treatment was 3.2 and 2.2 months, respectively. Median overall survival (mOS) for all patients was 6.2 months. mOS for first-line chemotherapy, second-line chemotherapy and BSC patients was 7.2, 4.5 and 2.0 months, respectively. Conclusions: First-line platinum-based chemotherapy is associated with notable response rates in mpSCC patients. Agents with better response rates are needed urgently potentially in combination with platinum-based chemotherapy. Level of evidence: Level 2b. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment
- Author
-
Andres, Maria Sol, primary, Ramalingam, Sivatharshini, additional, Rosen, Stuart D., additional, Baksi, John, additional, Khattar, Rajdeep, additional, Kirichenko, Yulia, additional, Young, Kate, additional, Yousaf, Nadia, additional, Okines, Alicia, additional, Huddart, Robert, additional, Harrington, Kevin, additional, Furness, Andrew, additional, Turajlic, Samra, additional, Pickering, Lisa, additional, Popat, Sanjay, additional, Larkin, James, additional, and Lyon, Alexander R., additional
- Published
- 2022
- Full Text
- View/download PDF
34. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
- Author
-
Fendler, Annika, Shepherd, Scott T C, Au, Lewis, Wu, Mary, Harvey, Ruth, Schmitt, Andreas M, Tippu, Zayd, Shum, Benjamin, Farag, Sheima, Rogiers, Aljosja, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Korteweg, Justine, Foley, Tara, Barber, Taja, Emslie-Henry, Andrea, Caulfield-Lynch, Niamh, Byrne, Fiona, Deng, Daqi, Kjaer, Svend, Song, Ok-Ryul, Queval, Christophe, Kavanagh, Caitlin, Wall, Emma C, Carr, Edward J, Caidan, Simon, Gavrielides, Mike, MacRae, James I, Kelly, Gavin, Peat, Kema, Kelly, Denise, Murra, Aida, Kelly, Kayleigh, O'Flaherty, Molly, Shea, Robyn L, Gardner, Gail, Murray, Darren, Yousaf, Nadia, Jhanji, Shaman, Tatham, Kate, Cunningham, David, Van As, Nicholas, Young, Kate, Furness, Andrew J S, Pickering, Lisa, Beale, Rupert, Swanton, Charles, Gandhi, Sonia, Gamblin, Steve, Bauer, David L V, Kassiotis, George, Howell, Michael, Nicholson, Emma, Walker, Susanna, Larkin, James, and Turajlic, Samra
- Published
- 2022
- Full Text
- View/download PDF
35. Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality
- Author
-
Coulton, Alexander, primary, Lobon, Irene, additional, Spain, Lavinia, additional, Rowan, Andrew, additional, Shnidrig, Desiree, additional, Shepherd, Scott, additional, Shum, Ben, additional, Byrne, Fiona, additional, Au, Lewis, additional, Edmonds, Kim, additional, Carlyle, Ellie, additional, Renn, Alexandra, additional, Messiou, Christina, additional, Spencer, Charlotte, additional, Schmidt, Andreas M., additional, Tippu, Zayd, additional, Rogiers, Aljosja, additional, Emmerich, Max, additional, Gerard, Camille, additional, Pallikonda, Husayn, additional, Naceur-Lombardelli, Cristina, additional, Foijer, Floris, additional, van den Bos, Hilda, additional, Wardenaar, René, additional, Spierings, Diana, additional, Young, Kate, additional, Pickering, Lisa, additional, Furness, Andrew, additional, Borg, Elaine, additional, Mitchison, Miriam, additional, Moore, David, additional, Falzon, Mary, additional, Proctor, Ian, additional, Stewart, Ruby, additional, Mahadeva, Ula, additional, Green, Anna, additional, Larkin, James, additional, Swanton, Charles, additional, Jamal-Hanjani, Mariam, additional, Litchfield, Kevin, additional, and Turajlic, Samra, additional
- Published
- 2022
- Full Text
- View/download PDF
36. Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality
- Author
-
Coulton, Alexander, primary, Lobon, Irene, additional, Spain, Lavinia, additional, Rowan, Andrew, additional, Shnidrig, Desiree, additional, Shepherd, Scott, additional, Shum, Ben, additional, Byrne, Fiona, additional, Au, Lewis, additional, Edmonds, Kim, additional, Carlyle, Ellie, additional, Renn, Alexandra, additional, Messiou, Christina, additional, Spencer, Charlotte, additional, Schmidt, Andreas M., additional, Tippu, Zayd, additional, Rogiers, Aljosja, additional, Emmerich, Max, additional, Gerard, Camille, additional, Pallikonda, Husayn, additional, Naceur-Lombardelli, Cristina, additional, Foijer, Floris, additional, van den Bos, Hilda, additional, Wardenaar, René, additional, Spierings, Diana, additional, Young, Kate, additional, Pickering, Lisa, additional, Furness, Andrew, additional, Borg, Elaine, additional, Mitchison, Miriam, additional, Moore, David, additional, Falzon, Mary, additional, Proctor, Ian, additional, Stewart, Ruby, additional, Mahadeva, Ula, additional, Green, Anna, additional, Larkin, James, additional, Swanton, Charles, additional, Jamal-Hanjani, Mariam, additional, Litchfield, Kevin, additional, and Turajlic, Samra, additional
- Published
- 2022
- Full Text
- View/download PDF
37. Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
- Author
-
Pires da Silva, Inês, primary, Ahmed, Tasnia, additional, McQuade, Jennifer L., additional, Nebhan, Caroline A., additional, Park, John J., additional, Versluis, Judith M., additional, Serra-Bellver, Patricio, additional, Khan, Yasir, additional, Slattery, Tim, additional, Oberoi, Honey K., additional, Ugurel, Selma, additional, Haydu, Lauren E., additional, Herbst, Rudolf, additional, Utikal, Jochen, additional, Pföhler, Claudia, additional, Terheyden, Patrick, additional, Weichenthal, Michael, additional, Gutzmer, Ralf, additional, Mohr, Peter, additional, Rai, Rajat, additional, Smith, Jessica L., additional, Scolyer, Richard A., additional, Arance, Ana M., additional, Pickering, Lisa, additional, Larkin, James, additional, Lorigan, Paul, additional, Blank, Christian U., additional, Schadendorf, Dirk, additional, Davies, Michael A., additional, Carlino, Matteo S., additional, Johnson, Douglas B., additional, Long, Georgina V., additional, Lo, Serigne N., additional, and Menzies, Alexander M., additional
- Published
- 2022
- Full Text
- View/download PDF
38. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
- Author
-
Fendler, Annika, primary, Shepherd, Scott T.C., additional, Au, Lewis, additional, Wilkinson, Katalin A., additional, Wu, Mary, additional, Schmitt, Andreas M., additional, Tippu, Zayd, additional, Farag, Sheima, additional, Rogiers, Aljosja, additional, Harvey, Ruth, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Del Rosario, Lyra, additional, Lingard, Karla, additional, Mangwende, Mary, additional, Holt, Lucy, additional, Ahmod, Hamid, additional, Korteweg, Justine, additional, Foley, Tara, additional, Barber, Taja, additional, Emslie-Henry, Andrea, additional, Caulfield-Lynch, Niamh, additional, Byrne, Fiona, additional, Shum, Benjamin, additional, Gerard, Camille L., additional, Deng, Daqi, additional, Kjaer, Svend, additional, Song, Ok-Ryul, additional, Queval, Christophe, additional, Kavanagh, Caitlin, additional, Wall, Emma C., additional, Carr, Edward J., additional, Namjou, Sina, additional, Caidan, Simon, additional, Gavrielides, Mike, additional, MacRae, James I., additional, Kelly, Gavin, additional, Peat, Kema, additional, Kelly, Denise, additional, Murra, Aida, additional, Kelly, Kayleigh, additional, O’Flaherty, Molly, additional, Shea, Robyn L., additional, Gardner, Gail, additional, Murray, Darren, additional, Popat, Sanjay, additional, Yousaf, Nadia, additional, Jhanji, Shaman, additional, Van As, Nicholas, additional, Young, Kate, additional, Furness, Andrew J.S., additional, Pickering, Lisa, additional, Beale, Rupert, additional, Swanton, Charles, additional, Gandhi, Sonia, additional, Gamblin, Steve, additional, Bauer, David L.V., additional, Kassiotis, George, additional, Howell, Michael, additional, Nicholson, Emma, additional, Walker, Susanna, additional, Wilkinson, Robert J., additional, Larkin, James, additional, and Turajlic, Samra, additional
- Published
- 2022
- Full Text
- View/download PDF
39. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
- Author
-
Orlando, Francesco, Romanel, Alessandro, Trujillo, Blanca, Sigouros, Michael, Wetterskog, Daniel, Quaini, Orsetta, Leone, Gianmarco, Xiang, Jenny Z, Wingate, Anna, Tagawa, Scott, Jayaram, Anuradha, Linch, Mark, Swanton, Charles, Jamal-Hanjani, Mariam, Abbosh, Chris, Zaccaria, Simone, Hessey, Sonya, Shiu, Kai-Keen, Bridgewater, John, Hochhauser, Daniel, Forster, Martin, Lee, Siow-Ming, Ahmad, Tanya, Papadatos-Pastos, Dionysis, Janes, Sam, Van Loo, Peter, Enfield, Katey, McGranahan, Nicholas, Huebner, Ariana, Quezada, Sergio, Beck, Stephan, Parker, Peter, Enver, Tariq, Hynds, Robert E, Dijkstra, Krijn, Pearce, David R, Falzon, Mary, Proctor, Ian, Sinclair, Ron, Lok, Chi-wah, Rhodes, Zoe, Moore, David, Marafioti, Teresa, Mitchison, Miriam, Ellery, Peter, Sivakumar, Monica, Brandner, Sebastian, Rowan, Andrew, Hiley, Crispin, Veeriah, Selvaraju, Shaw, Heather, Attard, Gert, Naceur-Lombardelli, Cristina, Toncheva, Antonia, Prymas, Paulina, Watkins, Tom, Bailey, Chris, Ruiz, Carlos Martinez, Litchfield, Kevin, Al-Bakir, Maise, Kanu, Nnenna, Ward, Sophie, Lim, Emilia, Reading, James, Chain, Benny, Alba, Blanca Trujillo, Akay, Melek, Flanagan, Adrienne, Biswas, Dhruva, Pich, Oriol, Dietzen, Michelle, Puttick, Clare, Colliver, Emma, Magness, Alistair, Angelova, Mihaela, Black, James, Lucas, Olivia, Hill, William, Liu, Wing-Kin, Frankell, Alexander, Magno, Neil, Athanasopoulou, Foteini, Wilson, Gareth, Rosenthal, Rachel, Salgado, Roberto, Lee, Claudia, Grigoriadis, Kristiana, Al-Sawaf, Othman, Karasaki, Takahiro, Bunkum, Abigail, Noorani, Imran, Benafif, Sarah, Barbe, Vittorio, Bola, Supreet, Vainauskas, Osvaldas, Hasan, Mahedi, Lise, Stefano, Leone, GianMarco, Alifrangis, Constantine, McGovern, Ursula, Thol, Kerstin, Gamble, Samuel, Ung, Seng Kuong, Sahwangarrom, Teerapon, Marin, Claudia Peinador, Wong, Sophia, Pawlik, Piotr, Gishen, Faye, Tookman, Adrian, Stone, Paddy, Stirling, Caroline, Turajlic, Samra, Larkin, James, Pickering, Lisa, Furness, Andrew, Young, Kate, Drake, Will, Edmonds, Kim, Hunter, Nikki, Mangwende, Mary, Pearce, Karla, Grostate, Lauren, Au, Lewis, Spain, Lavinia, Shepherd, Scott, Yan, Haixi, Shum, Ben, Tippu, Zayd, Hanley, Brian, Spencer, Charlotte, Emmerich, Max, Gerard, Camille, Schmitt, Andreas Michael, Del Rosario, Lyra, Carlyle, Eleanor, Lewis, Charlotte, Holt, Lucy, Lucanas, Analyn, O'Flaherty, Molly, Hazell, Steve, Mudhar, Hardeep, Messiou, Christina, Latifoltojar, Arash, Fendler, Annika, Byrne, Fiona, Pallinkonda, Husayn, Lobon, Irene, Coulton, Alex, Cattin, Anne Laure, Deng, Daqi, Feng, Geoffrey Hugang, Rowan, Andew, Yousaf, Nadia, Popat, Sanjay, Curtis, Olivia, Milner-Watts, Charlotte, Stamp, Gordon, Nye, Emma, Murra, Aida, Korteweg, Justine, Kelly, Denise, Terry, Lauren, Biano, Jennifer, Peat, Kema, Kelly, Kayleigh, Hill, Peter, Josephs, Debra, Irshad, Sheeba, Chandra, Ashish, Spicer, James, Mahadeva, Ula, Green, Anna, Stewart, Ruby, Iredale, Lara-Rose, Mackay, Tina, Deakin, Ben, Enting, Debra, Rudman, Sarah, Ghosh, Sharmistha, Karapagniotou, Lena, Pintus, Elias, Tutt, Andrew, Howlett, Sarah, Michalarea, Vasiliki, Brenton, James, Caldas, Carlos, Fitzgerald, Rebecca, Jimenez-Linan, Merche, Provenzano, Elena, Cluroe, Alison, Paterson, Anna, Aitken, Sarah, Allinson, Kieren, Stewart, Grant, McDermott, Ultan, Beddowes, Emma, Maughan, Tim, Ansorge, Olaf, Campbell, Peter, Roxburgh, Patricia, Fraser, Sioban, Kidd, Andrew, Blyth, Kevin, Le Quesne, John, Krebs, Matthew, Blackhall, Fiona, Summers, Yvonne, Oliveira, Pedro, Ortega-Franco, Ana, Dive, Caroline, Gomes, Fabio, Carter, Mat, Dransfield, Jo, Thomas, Anne, Fennell, Dean, Shaw, Jacqui, Naidu, Babu, Baijal, Shobhit, Tanchel, Bruce, Langman, Gerald, Robinson, Andrew, Collard, Martin, Cockcroft, Peter, Ferris, Charlotte, Bancroft, Hollie, Kerr, Amy, Middleton, Gary, Webb, Joanne, Kadiri, Salma, Colloby, Peter, Olisemeke, Bernard, Wilson, Rodelaine, Tomlinson, Ian, McNeish, Iain, Jogai, Sanjay, Holden, Samantha, Fernandes, Tania, Hampton, Blanche, McKenzie, Mairead, Hackshaw, Allan, Sharp, Abby, Chan, Kitty, Farrelly, Laura, Bridger, Hayley, Leslie, Rachel, Consortium, PEACE, Rubin, Mark A, Wyatt, Alexander W, Beltran, Himisha, Attard, Gerhardt, and Demichelis, Francesca
- Subjects
Chemical Biology & High Throughput ,Signalling & Oncogenes ,Human Biology & Physiology ,Ecology,Evolution & Ethology ,Genome Integrity & Repair ,Tumour Biology ,Genetics & Genomics ,Computational & Systems Biology - Abstract
Sequencing of cell-free DNA (cfDNA) in cancer patients’ plasma offers a minimally-invasive solution to detect tumor cell genomic alterations to aid real-time clinical decision-making. The reliability of copy number detection decreases at lower cfDNA tumor fractions, limiting utility at earlier stages of the disease. To test a novel strategy for detection of allelic imbalance, we developed a prostate cancer bespoke assay, PCF_SELECT, that includes an innovative sequencing panel covering ∼25 000 high minor allele frequency SNPs and tailored analytical solutions to enable allele-informed evaluation. First, we assessed it on plasma samples from 50 advanced prostate cancer patients. We then confirmed improved detection of genomic alterations in samples with
- Published
- 2022
- Full Text
- View/download PDF
40. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
- Author
-
Fendler, Annika, Shepherd, Scott TC, Au, Lewis, Wilkinson, Katalin A, Wu, Mary, Byrne, Fiona, Cerrone, Maddalena, Schmitt, Andreas M, Joharatnam-Hogan, Nalinie, Shum, Benjamin, Tippu, Zayd, Rzeniewicz, Karolina, Boos, Laura Amanda, Harvey, Ruth, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Sarker, Sarah, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Korteweg, Justine, Foley, Tara, Bazin, Jessica, Gordon, William, Barber, Taja, Emslie-Henry, Andrea, Xie, Wenyi, Gerard, Camille L, Deng, Daqi, Wall, Emma C, Agua-Doce, Ana, Namjou, Sina, Caidan, Simon, Gavrielides, Mike, MacRae, James I, Kelly, Gavin, Peat, Kema, Kelly, Denise, Murra, Aida, Kelly, Kayleigh, O���Flaherty, Molly, Dowdie, Lauren, Ash, Natalie, Gronthoud, Firza, Shea, Robyn L, Gardner, Gail, Murray, Darren, Kinnaird, Fiona, Cui, Wanyuan, Pascual, Javier, Rodney, Simon, Mencel, Justin, Curtis, Olivia, Stephenson, Clemency, Robinson, Anna, Oza, Bhavna, Farag, Sheima, Leslie, Isla, Rogiers, Aljosja, Iyengar, Sunil, Ethell, Mark, Messiou, Christina, Cunningham, David, Chau, Ian, Starling, Naureen, Turner, Nicholas, Welsh, Liam, van As, Nicholas, Jones, Robin L, Droney, Joanne, Banerjee, Susana, Tatham, Kate C, O���Brien, Mary, Harrington, Kevin, Bhide, Shreerang, Okines, Alicia, Reid, Alison, Young, Kate, Furness, Andrew JS, Pickering, Lisa, Swanton, Charles, Consortium, The Crick COVID-19, Gandhi, Sonia, Gamblin, Steve, Bauer, David LV, Kassiotis, George, Kumar, Sacheen, Yousaf, Nadia, Jhanji, Shaman, Nicholson, Emma, Howell, Michael, Walker, Susanna, Wilkinson, Robert J, Larkin, James, Turajlic, Samra, and Consortium, The CAPTURE
- Subjects
Model organisms ,Chemical Biology & High Throughput ,Human Biology & Physiology ,FOS: Clinical medicine ,Stem Cells ,Genome Integrity & Repair ,Immunology ,Neurosciences ,Infectious Disease ,Cell Biology ,Tumour Biology ,Biochemistry & Proteomics ,Signalling & Oncogenes ,Metabolism ,Ecology,Evolution & Ethology ,Cell Cycle & Chromosomes ,Genetics & Genomics ,Developmental Biology ,Structural Biology & Biophysics ,Computational & Systems Biology - Abstract
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.
- Published
- 2022
- Full Text
- View/download PDF
41. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
- Author
-
Fendler, Annika, Au, Lewis, Shepherd, Scott TC, Byrne, Fiona, Cerrone, Maddalena, Boos, Laura Amanda, Rzeniewicz, Karolina, Gordon, William, Shum, Benjamin, Gerard, Camille L, Ward, Barry, Xie, Wenyi, Schmitt, Andreas M, Joharatnam-Hogan, Nalinie, Cornish, Georgina H, Pule, Martin, Mekkaoui, Leila, Ng, Kevin W, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Sarker, Sarah, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Stone, Richard, Gomes, Camila, Flynn, Helen R, Agua-Doce, Ana, Hobson, Philip, Caidan, Simon, Howell, Michael, Wu, Mary, Goldstone, Robert, Crawford, Margaret, Cubitt, Laura, Patel, Harshil, Gavrielides, Mike, Nye, Emma, Snijders, Ambrosius P, MacRae, James I, Nicod, Jerome, Gronthoud, Firza, Shea, Robyn L, Messiou, Christina, Cunningham, David, Chau, Ian, Starling, Naureen, Turner, Nicholas, Welsh, Liam, van As, Nicholas, Jones, Robin L, Droney, Joanne, Banerjee, Susana, Tatham, Kate C, Jhanji, Shaman, O���Brien, Mary, Curtis, Olivia, Harrington, Kevin, Bhide, Shreerang, Bazin, Jessica, Robinson, Anna, Stephenson, Clemency, Slattery, Tim, Khan, Yasir, Tippu, Zayd, Leslie, Isla, Gennatas, Spyridon, Okines, Alicia, Reid, Alison, Young, Kate, Furness, Andrew JS, Pickering, Lisa, Gandhi, Sonia, Gamblin, Steve, Swanton, Charles, Consortium, The Crick COVID-19, Nicholson, Emma, Kumar, Sacheen, Yousaf, Nadia, Wilkinson, Katalin A, Swerdlow, Anthony, Harvey, Ruth, Kassiotis, George, Larkin, James, Wilkinson, Robert J, Turajlic, Samra, and consortium, The CAPTURE
- Subjects
Model organisms ,Chemical Biology & High Throughput ,Human Biology & Physiology ,FOS: Clinical medicine ,Stem Cells ,Genome Integrity & Repair ,Immunology ,Neurosciences ,Infectious Disease ,Cell Biology ,Tumour Biology ,Biochemistry & Proteomics ,Signalling & Oncogenes ,Metabolism ,Ecology,Evolution & Ethology ,Cell Cycle & Chromosomes ,Genetics & Genomics ,Developmental Biology ,Structural Biology & Biophysics ,Computational & Systems Biology - Abstract
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.
- Published
- 2022
- Full Text
- View/download PDF
42. Real-World Outcomes with Ipilimumab and Nivolumab in Advanced Melanoma: A Multicentre Retrospective Study
- Author
-
Serra-Bellver, Patricio, primary, Versluis, Judith M., additional, Oberoi, Honey K., additional, Zhou, Cong, additional, Slattery, Timothy D., additional, Khan, Yasir, additional, Patrinely, James R., additional, Pires da Silva, Ines, additional, Martinez-Vila, Clara, additional, Cook, Natalie, additional, Graham, Donna, additional, Carlino, Matteo, additional, Menzies, Alexander M., additional, Arance, Ana M., additional, Douglas, Douglas B., additional, Long, Georgina V., additional, Pickering, Lisa, additional, Larkin, James M. G., additional, Blank, Christian U., additional, and Lorigan, Paul, additional
- Published
- 2022
- Full Text
- View/download PDF
43. Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancer
- Author
-
Fendler, Annika, primary, Shepherd, Scott T.C., additional, Au, Lewis, additional, Wilkinson, Katalin A., additional, Wu, Mary, additional, Schmitt, Andreas M., additional, Tippu, Zayd, additional, Farag, Sheima, additional, Rogiers, Aljosja, additional, Harvey, Ruth, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Rosario, Lyra Del, additional, Lingard, Karla, additional, Mangwende, Mary, additional, Holt, Lucy, additional, Ahmod, Hamid, additional, Korteweg, Justine, additional, Foley, Tara, additional, Barber, Taja, additional, Emslie-Henry, Andrea, additional, Caulfield-Lynch, Niamh, additional, Byrne, Fiona, additional, Shum, Benjamin, additional, Gerard, Camille L., additional, Deng, Daqi, additional, Kjaer, Svend, additional, Song, Ok-Ryul, additional, Queval, Christophe, additional, Kavanagh, Caitlin, additional, Wall, Emma C., additional, Carr, Edward J., additional, Namjou, Sina, additional, Caidan, Simon, additional, Gavrielidis, Mike, additional, McRae, James, additional, Kelly, Gavin, additional, Peat, Kema, additional, Kelly, Denise, additional, Murra, Aida, additional, Kelly, Kayleigh, additional, O'Flaherty, Molly, additional, Shea, Robyn L., additional, Gardner, Gail, additional, Murray, Darren, additional, Yousaf, Nadia, additional, Jhanji, Shaman, additional, As, Nicholas Van, additional, Young, Kate, additional, Furness, Andre J.S., additional, Pickering, Lisa, additional, Beale, Rupert, additional, Swanton, Charles, additional, Ghandi, Sonia, additional, Gamblin, Steve, additional, Bauer, David L.V., additional, Kassiotis, George, additional, Howell, Michael, additional, Nicholson, Emma, additional, Wilkinson, Robert J., additional, Larkin, James, additional, and Turajlic, Samra, additional
- Published
- 2021
- Full Text
- View/download PDF
44. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
- Author
-
Au, Lewis, Hatipoglu, Emine, Robert De Massy, Marc, Litchfield, Kevin, Beattie, Gordon, Rowan, Andrew, Schnidrig, Desiree, Thompson, Rachael, Byrne, Fiona, Horswell, Stuart, Fotiadis, Nicos, Hazell, Steve, Nicol, David, Shepherd, Scott TC, Fendler, Annika, Mason, Robert, Del Rosario, Lyra, Edmonds, Kim, Lingard, Karla, Sarker, Sarah, Mangwende, Mary, Carlyle, Eleanor, Attig, Jan, Joshi, Kroopa, Uddin, Imran, Becker, Pablo D, Sunderland, Mariana Werner, Akarca, Ayse, Puccio, Ignazio, Yang, William W, Lund, Tom, Dhillon, Kim, Vasquez, Marcos Duran, Ghorani, Ehsan, Xu, Hang, Spencer, Charlotte, López, José I, Green, Anna, Mahadeva, Ula, Borg, Elaine, Mitchison, Miriam, Moore, David A, Proctor, Ian, Falzon, Mary, Pickering, Lisa, Furness, Andrew JS, Reading, James L, Salgado, Roberto, Marafioti, Teresa, Jamal-Hanjani, Mariam, PEACE Consortium, Kassiotis, George, Chain, Benny, Larkin, James, Swanton, Charles, Quezada, Sergio A, Turajlic, Samra, TRACERx Renal Consortium, and Apollo - University of Cambridge Repository
- Subjects
multiregion ,Receptors, Antigen, T-Cell ,clear cell renal cell carcinoma ,CD8-Positive T-Lymphocytes ,autopsy ,Clinical Trials, Phase II as Topic ,Exome Sequencing ,Tumor Microenvironment ,Humans ,TCR clonal replacement ,Prospective Studies ,TCR clonal maintenance ,Carcinoma, Renal Cell ,Immune Checkpoint Inhibitors ,nivolumab ,Sequence Analysis, RNA ,Gene Expression Profiling ,Endogenous Retroviruses ,Genomics ,Kidney Neoplasms ,human endogenous retrovirus ,Drug Resistance, Neoplasm ,anti-PD-1 ,Tumor Escape ,T cell receptor ,Single-Cell Analysis - Abstract
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between tumor molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indirectly correlates with clinical response. T cell receptor (TCR) analysis reveals a significantly higher number of expanded TCR clones pre-treatment in responders suggesting pre-existing immunity. Maintenance of highly similar clusters of TCRs post-treatment predict response, suggesting ongoing antigen engagement and survival of families of T cells likely recognizing the same antigens. In responders, nivolumab-bound CD8+ T cells are expanded and express GZMK/B. Our data suggest nivolumab drives both maintenance and replacement of previously expanded T cell clones, but only maintenance correlates with response. We hypothesize that maintenance and boosting of a pre-existing response is a key element of anti-PD-1 mode of action.
- Published
- 2021
45. Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial
- Author
-
Halabi, Susan, Yang, Qian, Carmack, Andrea, Zhang, Shiqi, Foo, Wen-Chi, Eisen, Tim, Stadler, Walter, Jones, Robert J., Garcia, Jorge, Picus, Joel, Hawkins, Robert, Hainsworth, John, Kollmannsberger, Christian, Logan, Theodore, Puzanov, Igor, Pickering, Lisa, Ryan, Christopher, Protheroe, Andrew, George, Daniel, and Armstrong, Andrew
- Abstract
Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC), particularly papillary renal cell carcinoma, in order to inform on initial treatment selection and identify potentially novel targets for therapy. We enrolled 108 patients in ASPEN, an international randomized open-label phase 2 trial of patients with metastatic papillary, chromophobe, or unclassified NC-RCC treated with the mTOR inhibitor everolimus (n=57) or the vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib (n=51), stratified by MSKCC risk and histology. The primary endpoint was overall survival (OS) and secondary efficacy endpoints for this exploratory biomarker analysis were radiographic progression-free survival (rPFS) defined by intentionto- treat using the RECIST 1.1 criteria and radiographic response rates. Tissue biomarkers (n=78) of mTOR pathway activation (phospho-S6 and -Akt, c-kit) and VEGF pathway activation (HIF-1, c-MET) were prospectively explored in tumor tissue by immunohistochemistry prior to treatment and associated with clinical outcomes. We found that S6 activation was more common in poor-risk NC-RCC tumors and S6/Akt activation was associated with worse PFS and OS outcomes with both everolimus and sunitinib, while c-kit was commonly expressed in chromophobe tumors and associated with improved outcomes with both agents. C-MET was commonly expressed in papillary tumors and was associated with lower rates of radiographic response but did not predict PFS for either agent. In multivariable analysis, both pAkt and c-kit were statistically significant prognostic biomarkers of OS. No predictive biomarkers of treatment response were identified for clinical outcomes. Most biomarker subgroups had improved outcomes with sunitinib as compared to everolimus.
- Published
- 2021
46. Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma
- Author
-
Armstrong, Andrew J., Nixon, Andrew B., Carmack, Andrea, Eisen, Tim, Stadler, Walter M., Jones, Robert J., Garcia, Jorge A., Vaishampayan, Ulka N., Picus, Joel, Hawkins, Robert E., Hainsworth, John D., Kollmannsberger, Christian K., Logan, Theodore F., Puzanov, Igor, Pickering, Lisa M., Ryan, Christopher W., Protheroe, Andrew, George, Daniel J., and Halabi, Susan
- Subjects
urologic and male genital diseases - Abstract
Purpose: Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC) to inform treatment selection but also to identify novel therapeutic targets. We thus sought to profile circulating angiokines in the context of a randomized treatment trial of everolimus versus sunitinib. \ud \ud Experimental Design: ASPEN (NCT01108445) was an international, randomized, open-label phase 2 trial of patients with metastatic papillary, chromophobe, or unclassified NC-RCC with no prior systemic therapy. Patients were randomized to everolimus or sunitinib and treated until disease progression or unacceptable toxicity. The primary endpoint was radiographic progression-free survival (PFS) defined by RECIST 1.1 criteria. Plasma angiokines were collected at baseline, cycle 3, and progression and associated with PFS and overall survival. \ud \ud Results: We enrolled 108 patients, 51 received sunitinib and 57 everolimus; of these, 89 patients had evaluable plasma for 23 angiokines. At the final data cutoff, 87 PFS and 62 mortality events had occurred. Angiokines that were independently adversely prognostic for OS were osteopontin (OPN), HGF, and VCAM-1, and these were also associated with poor risk disease. SDF-1 was associated with improved survival. OPN was also significantly associated with worse PFS. No statistically significant angiokine-treatment outcome interactions were observed for sunitinib or everolimus. OPN, HGF, TIMP-1, VCAM-1, PDGF-AA and IL-6 levels increased with progression on everolimus, while OPN, PlGF, TIMP-1, VEGF, and soluble VEGFR-2 and VCAM-1 increased with progression on sunitinib. \ud \ud Conclusions: In patients with metastatic non-clear cell RCC, we identified several poor prognosis angiokines and immunomodulatory chemokines during treatment with sunitinib or everolimus, particularly OPN.
- Published
- 2021
47. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
- Author
-
Au, Lewis, primary, Hatipoglu, Emine, additional, Robert de Massy, Marc, additional, Litchfield, Kevin, additional, Beattie, Gordon, additional, Rowan, Andrew, additional, Schnidrig, Desiree, additional, Thompson, Rachael, additional, Byrne, Fiona, additional, Horswell, Stuart, additional, Fotiadis, Nicos, additional, Hazell, Steve, additional, Nicol, David, additional, Shepherd, Scott T.C., additional, Fendler, Annika, additional, Mason, Robert, additional, Del Rosario, Lyra, additional, Edmonds, Kim, additional, Lingard, Karla, additional, Sarker, Sarah, additional, Mangwende, Mary, additional, Carlyle, Eleanor, additional, Attig, Jan, additional, Joshi, Kroopa, additional, Uddin, Imran, additional, Becker, Pablo D., additional, Sunderland, Mariana Werner, additional, Akarca, Ayse, additional, Puccio, Ignazio, additional, Yang, William W., additional, Lund, Tom, additional, Dhillon, Kim, additional, Vasquez, Marcos Duran, additional, Ghorani, Ehsan, additional, Xu, Hang, additional, Spencer, Charlotte, additional, López, José I., additional, Green, Anna, additional, Mahadeva, Ula, additional, Borg, Elaine, additional, Mitchison, Miriam, additional, Moore, David A., additional, Proctor, Ian, additional, Falzon, Mary, additional, Pickering, Lisa, additional, Furness, Andrew J.S., additional, Reading, James L., additional, Salgado, Roberto, additional, Marafioti, Teresa, additional, Jamal-Hanjani, Mariam, additional, Kassiotis, George, additional, Chain, Benny, additional, Larkin, James, additional, Swanton, Charles, additional, Quezada, Sergio A., additional, Turajlic, Samra, additional, Abbosh, Chris, additional, Shiu, Kai-Keen, additional, Bridgewater, John, additional, Hochhauser, Daniel, additional, Forster, Martin, additional, Lee, Siow-Ming, additional, Ahmad, Tanya, additional, Papadatos-Pastos, Dionysis, additional, Janes, Sam, additional, Van Loo, Peter, additional, Enfield, Katey, additional, McGranahan, Nicholas, additional, Huebner, Ariana, additional, Beck, Stephan, additional, Parker, Peter, additional, Walczak, Henning, additional, Enver, Tariq, additional, Hynds, Rob, additional, Sinclair, Ron, additional, Lok, Chi-wah, additional, Rhodes, Zoe, additional, Moore, David, additional, Khiroya, Reena, additional, Trevisan, Giorgia, additional, Ellery, Peter, additional, Linch, Mark, additional, Brandner, Sebastian, additional, Hiley, Crispin, additional, Veeriah, Selvaraju, additional, Razaq, Maryam, additional, Shaw, Heather, additional, Attard, Gert, additional, Akther, Mita Afroza, additional, Naceur-Lombardelli, Cristina, additional, Manzano, Lizi, additional, Al-Bakir, Maise, additional, Summan, Simranpreet, additional, Kanu, Nnenna, additional, Ward, Sophie, additional, Asghar, Uzma, additional, Lim, Emilia, additional, Gishen, Faye, additional, Tookman, Adrian, additional, Stone, Paddy, additional, Stirling, Caroline, additional, Hunter, Nikki, additional, Vaughan, Sarah, additional, Spain, Lavinia, additional, Yan, Haixi, additional, Shum, Ben, additional, Yousaf, Nadia, additional, Popat, Sanjay, additional, Curtis, Olivia, additional, Stamp, Gordon, additional, Toncheva, Antonia, additional, Nye, Emma, additional, Murra, Aida, additional, Korteweg, Justine, additional, Josephs, Debra, additional, Chandra, Ashish, additional, Spicer, James, additional, Stewart, Ruby, additional, Iredale, Lara-Rose, additional, Mackay, Tina, additional, Deakin, Ben, additional, Enting, Debra, additional, Rudman, Sarah, additional, Ghosh, Sharmistha, additional, Karapagniotou, Lena, additional, Pintus, Elias, additional, Tutt, Andrew, additional, Howlett, Sarah, additional, Michalarea, Vasiliki, additional, Brenton, James, additional, Caldas, Carlos, additional, Fitzgerald, Rebecca, additional, Jimenez-Linan, Merche, additional, Provenzano, Elena, additional, Cluroe, Alison, additional, Stewart, Grant, additional, Watts, Colin, additional, Gilbertson, Richard, additional, McDermott, Ultan, additional, Tavare, Simon, additional, Beddowes, Emma, additional, Roxburgh, Patricia, additional, Biankin, Andrew, additional, Chalmers, Anthony, additional, Fraser, Sioban, additional, Oien, Karin, additional, Kidd, Andrew, additional, Blyth, Kevin, additional, Krebs, Matt, additional, Blackhall, Fiona, additional, Summers, Yvonne, additional, Dive, Caroline, additional, Marais, Richard, additional, Gomes, Fabio, additional, Carter, Mat, additional, Dransfield, Jo, additional, Le Quesne, John, additional, Fennell, Dean, additional, Shaw, Jacqui, additional, Naidu, Babu, additional, Baijal, Shobhit, additional, Tanchel, Bruce, additional, Langman, Gerald, additional, Robinson, Andrew, additional, Collard, Martin, additional, Cockcroft, Peter, additional, Ferris, Charlotte, additional, Bancroft, Hollie, additional, Kerr, Amy, additional, Middleton, Gary, additional, Webb, Joanne, additional, Kadiri, Salma, additional, Colloby, Peter, additional, Olisemeke, Bernard, additional, Wilson, Rodelaine, additional, Tomlinson, Ian, additional, Jogai, Sanjay, additional, Ottensmeier, Christian, additional, Harrison, David, additional, Loda, Massimo, additional, Flanagan, Adrienne, additional, McKenzie, Mairead, additional, Hackshaw, Allan, additional, Ledermann, Jonathan, additional, Chan, Kitty, additional, Sharp, Abby, additional, Farrelly, Laura, additional, Bridger, Hayley, additional, Challacombe, Ben, additional, Chowdhury, Simon, additional, Drake, William, additional, Fernando, Archana, additional, Harrison-Phipps, Karen, additional, Hill, Peter, additional, Horsfield, Catherine, additional, O'Brien, Tim, additional, Olsburgh, Jonathon, additional, Polson, Alexander, additional, Varia, Mary, additional, and Verma, Hema, additional
- Published
- 2021
- Full Text
- View/download PDF
48. VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis
- Author
-
Nicholson, Steve, primary, Tovey, Holly, additional, Elliott, Tony, additional, Burnett, Stephanie M., additional, Cruickshank, Clare, additional, Bahl, Amit, additional, Kirkbride, Peter, additional, Mitra, Anita V., additional, Thomson, Alastair H., additional, Vasudev, Naveen, additional, Venugopal, Balaji, additional, Slade, Rachel, additional, Tregellas, Lucy, additional, Morgan, Bruno, additional, Hassall, Alison, additional, Hall, Emma, additional, and Pickering, Lisa M., additional
- Published
- 2021
- Full Text
- View/download PDF
49. mTOR and VEGF Tissue Biomarkers and Sunitinib/Everolimus Outcomes in Non-Clear Cell Renal Cancer
- Author
-
Halabi, Susan, primary, Yang, Qian, additional, Carmack, Andrea, additional, Zhang, Shiqi, additional, Foo, Wen-Chi, additional, Eisen, Tim, additional, Stadler, Walter, additional, Jones, Robert J., additional, Garcia, Jorge, additional, Vaishampayan, Ulka, additional, Picus, Joel, additional, Hawkins, Robert, additional, Hainsworth, John, additional, Kollmannsberger, Christian, additional, Logan, Theodore, additional, Puzanov, Igor, additional, Pickering, Lisa, additional, Ryan, Christopher, additional, Protheroe, Andrew, additional, George, Daniel, additional, and Armstrong, Andrew, additional
- Published
- 2021
- Full Text
- View/download PDF
50. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study
- Author
-
Fendler, Annika, primary, Shepherd, Scott, additional, Au, Lewis, additional, Wilkinson, Katalin, additional, Wu, Mary, additional, Byrne, Fiona, additional, Cerrone, Maddalena, additional, Schmitt, Andreas, additional, Joharatnam-Hogan, Nalinie, additional, Shum, Ben, additional, Tippu, Zayd, additional, Rzeniewicz, Karolina, additional, Boos, Laura, additional, Harvey, Ruth, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Rosario, Lyra Del, additional, Sarker, Sarah, additional, Lingard, Karla, additional, Mangwende, Mary, additional, Holt, Lucy, additional, Ahmod, Hamid, additional, Koreweg, Justine, additional, Foley, Tara, additional, Bazin, Jessica, additional, Gordon, William, additional, Barber, Taja, additional, Emslie-Henry, Andrea, additional, Xie, Wenyi, additional, Gerard, Camille, additional, Deng, Daqi, additional, Wall, Emma, additional, Agua-Doce, Ana, additional, Namjou, Sina, additional, Caidan, Simon, additional, Gavrielides, Mike, additional, MacRae, James, additional, Kelly, Gavin, additional, Peat, Kema, additional, Kelly, Denise, additional, Murra, Aida, additional, Kelly, Kayleigh, additional, O'Flaherty, Molly, additional, Dowdie, Lauren, additional, Ash, Natalie, additional, Grounthoud, Firza, additional, Shea, Robyn, additional, Gardner, Gail, additional, Murray, Darren, additional, Kinnaird, Fiona, additional, Cui, Wanyuan, additional, Pascual, Javier, additional, Rodney, Simon, additional, Mencel, Justin, additional, Curtis, Olivia, additional, Stephenson, Clemency, additional, Robinson, Anna, additional, Oza, Bhavna, additional, Farag, Sheima, additional, Leslie, Isla, additional, Rogiers, Aljosja, additional, Lyengar, Sunil, additional, Ethell, Mark, additional, Messiou, Christina, additional, Cunningham, David, additional, Chau, Ian, additional, Starling, Naureen, additional, Turner, Nicholas, additional, Welsh, Liam, additional, As, Nicholas van, additional, Jones, Robin, additional, DRoney, Joanne, additional, Banerjee, Susana, additional, Tatham, Kate, additional, O'Brien, Mary, additional, Harrington, Kevin, additional, Bhide, Shreerang, additional, Okines, Alicia, additional, Reid, Alison, additional, Young, Kate, additional, Furness, Andrew, additional, Pickering, Lisa, additional, Swanton, Charles, additional, Gandhi, Sonia, additional, Gamblin, Steve, additional, Bauer, David, additional, Kassiotis, George, additional, Kumar, Sacheen, additional, Yousaf, Nadia, additional, Jhanji, Shaman, additional, Nicholson, Emma, additional, Howell, Michael, additional, Walker, Susanna, additional, Wilkinson, Robert, additional, Larkin, James, additional, and Turajlic, Samra, additional
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.